Indaptus Therapeutics (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.
The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.
The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.
Shares of the company were down 1.3% in recent trading.
Price: 0.89, Change: -0.01, Percent Change: -1.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.